Previous Close | 5.29 |
Open | 5.24 |
Bid | 5.12 x 3100 |
Ask | 5.13 x 4000 |
Day's Range | 5.10 - 5.37 |
52 Week Range | 3.53 - 11.36 |
Volume | |
Avg. Volume | 9,170,655 |
Market Cap | 719.358M |
Beta (5Y Monthly) | 1.58 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.41 |
Earnings Date | May 07, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 15.40 |
Subscribe to Yahoo Finance Plus to view Fair Value for NVAX
For this biotech, a rebound seems far too unlikely.
There’s a simple reason why short-squeeze stocks to buy represent a powerful catalyst: they’re intuitive and easier to engage. Buying something and hoping that it appreciates in value represents an organically sensible strategy. It’s the reason why people collect everything from baseball cards to luxury Swiss watches. Stated differently, it doesn’t take much to explain the rationale behind short-squeeze stocks to buy. On the other hand, shorting a stock represents an incredibly complex affair by
Could these biotech companies still win in the vaccine market and beyond?